RU2002102076A - PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND ORLISTAT - Google Patents

Claims (8)

1. A method of treating concomitant pathological conditions associated with obesity in a person in need of such treatment, which comprises administering to that person a therapeutic effective amount of a compound of formula I

including its enantiomers and pharmaceutically acceptable salts in which R ₁ and R _{2 are} independently H or methyl, and a therapeutically effective amount of a compound of formula II

moreover, the compound of formula I and the compound of formula II are taken simultaneously, individually or sequentially. 2. The method according to claim 1, characterized in that the compound of formula I is a

- {1- [1- (4-chlorophenyl) cyclobutyl] -3-methylbutyl} -

dimethylamine or its salt. 3. The method according to claim 2, characterized in that the compound of formula I is taken in the period from 30 minutes to 3 hours before receiving the compounds of formula II. 4. The compound of formula I, including its enantiomers and pharmaceutically acceptable salts, in which R ₁ and R ₂ independently mean H or methyl, and the compound of formula II, intended for the treatment of concomitant pathological conditions associated with obesity, by administration performed simultaneously, individually or sequentially. 5. The compound of formula I, including its enantiomers and pharmaceutically acceptable salts, in which R ₁ and R ₂ independently mean H or methyl, and the compound of formula II as a combined preparation for the treatment of concomitant pathological conditions associated with obesity, by reception performed simultaneously, individually or sequentially. 6. A product containing a compound of formula I, including its enantiomers and pharmaceutically acceptable salts, in which R ₁ and R _{2 are} independently H or methyl, and a compound of formula II as a combination preparation for the treatment of concomitant pathological conditions associated with obesity, by admission performed simultaneously, individually or sequentially. 7. The use of a product containing a compound of formula I, including its enantiomers and pharmaceutically acceptable salts, in which R ₁ and R _{2 are} independently H or methyl, for the manufacture of a medicament for the treatment of concomitant pathological conditions associated with obesity, in a patient who is also receiving treatment with orlistat. 8. A pharmaceutical composition comprising a compound of formula I

including its enantiomers and pharmaceutically acceptable salts, in which R ₁ and R ₂ independently mean H or methyl, and a compound of formula II

together with a pharmaceutically acceptable diluent or carrier.